ASH 2021 | Clonal hematopoiesis in patients with multiple myeloma
Tarek H Mouhieddine, MD, Icahn School of Medicine at Mount Sinai, New York, NY, gives an overview of the results of a study investigating clonal hematopoiesis in patients with multiple myeloma with and without an autologous stem cell transplant (ASCT). The study included patients from the Multiple Myeloma Research Foundation (MMRF) cohort who had both tumor and peripheral blood samples with whole-exome sequencing (WES) data taken at baseline and during treatment. Consistent with previous studies examining transplanted patients, it was found that clonal hematopoiesis was associated with a shorter progression-free survival (PFS) and that the incidence of clonal hematopoiesis increased during the course of the treatment. In the future, it will be interesting to explore the long-term consequences of clonal hematopoiesis as well as the impact of treatment on this phenomenon. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
